Literature DB >> 28169459

Long-term effectiveness and complication rates of bladder augmentation in patients with neurogenic bladder dysfunction: A systematic review.

Lisette 't Hoen1, Hazel Ecclestone2, Bertil F M Blok1, Gilles Karsenty3, Véronique Phé4,5, Romain Bossier3, Jan Groen1, David Castro-Diaz4,5, Bárbara Padilla Fernández4,5, Giulio Del Popolo6, Stefania Musco6, Jürgen Pannek7, Thomas M Kessler8, Tobias Gross9, Marc P Schneider8, Rizwan Hamid2.   

Abstract

AIMS: To systematically evaluate effectiveness and safety of bladder augmentation for adult neuro-urological patients.
METHODS: The Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement was followed for review of publications. The Medline, Embase, and Cochrane controlled trial databases and clinicaltrial.gov were searched until January 2015. No limitations were placed on date or language. Non-original articles, conference abstracts, and publications involving children and animals were excluded. Risk-of-bias and confounder assessment was performed.
RESULTS: A total of 20 studies including 511 patients were eligible for inclusion. The level of evidence for the included studies was low, most level 4 studies with only one level 3 study. The data were narratively synthesized. Across all studies high risk-of bias and confounding was found. Primary outcomes were assessed in 16 of the 20 studies and showed improved quality of life and anatomical changes as well as stable renal function. The secondary outcomes were reported in 17 of the 20 studies and urodynamic parameters and continence all demonstrated improvement after bladder reconstruction. Long-term complications continued up to 10 years post-operatively, including bowel dysfunction in 15% of the patients, stone formation in 10%, five bladder perforations and one bladder cancer.
CONCLUSIONS: Available studies are not plentiful and of relatively poor quality, appropriately designed prospective studies are urgently needed. Despite this, bladder augmentation appears to be a highly effective procedure at protecting the upper urinary tract and improving quality of life. However, it is associated with relatively high morbidity in both the short and long term.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  bladder augmentation; bladder dysfunction; bowel segment; neurogenic patients; systematic review

Mesh:

Year:  2017        PMID: 28169459     DOI: 10.1002/nau.23205

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  10 in total

1.  Urologic care and progression to end-stage kidney disease: a Chronic Kidney Disease in Children (CKiD) nested case-control study.

Authors:  D I Chu; A G Abraham; G E Tasian; M R Denburg; M E Ross; S A Zderic; S L Furth
Journal:  J Pediatr Urol       Date:  2019-03-16       Impact factor: 1.830

2.  Enterocystoplasty and appendicovesicostomy in adults: a description of demographics and 30-day outcomes of bladder augmentation.

Authors:  Joseph G Brungardt; Caleb S Miller; Kurt P Schropp
Journal:  Am J Clin Exp Urol       Date:  2020-08-15

3.  Bladder Augmentation Using Lyoplant®: First Experimental Results in Rats.

Authors:  F Winde; K Backhaus; J A Zeitler; N Schlegel; Th Meyer
Journal:  Tissue Eng Regen Med       Date:  2019-09-26       Impact factor: 4.169

4.  Application of antibody-conjugated small intestine submucosa to capture urine-derived stem cells for bladder repair in a rabbit model.

Authors:  Yu-Ting Song; Yan-Qing Li; Mao-Xuan Tian; Jun-Gen Hu; Xiu-Ru Zhang; Peng-Cheng Liu; Xiu-Zhen Zhang; Qing-Yi Zhang; Li Zhou; Long-Mei Zhao; Jesse Li-Ling; Hui-Qi Xie
Journal:  Bioact Mater       Date:  2021-11-27

5.  Augmentation cystoplasty in children with stages III and IV chronic kidney disease secondary to neurogenic bladder.

Authors:  Sanjay Sinha; Mehul Shah
Journal:  Asian J Urol       Date:  2021-06-01

6.  Improved contractile potential in detrusor microtissues from pediatric patients with end stage lower urinary tract dysfunction.

Authors:  Tim Gerwinn; Souzan Salemi; Larissa J Schori; Dafni Planta; Daniel Eberli; Maya Horst
Journal:  Front Cell Dev Biol       Date:  2022-10-04

7.  TASCI-transcutaneous tibial nerve stimulation in patients with acute spinal cord injury to prevent neurogenic detrusor overactivity: protocol for a nationwide, randomised, sham-controlled, double-blind clinical trial.

Authors:  Veronika Birkhäuser; Martina D Liechti; Collene E Anderson; Lucas M Bachmann; Sarah Baumann; Michael Baumberger; Lori A Birder; Sander M Botter; Silvan Büeler; Célia D Cruz; Gergely David; Patrick Freund; Susanne Friedl; Oliver Gross; Margret Hund-Georgiadis; Knut Husmann; Xavier Jordan; Miriam Koschorke; Lorenz Leitner; Eugenia Luca; Ulrich Mehnert; Sandra Möhr; Freschta Mohammadzada; Katia Monastyrskaya; Nikolai Pfender; Daniel Pohl; Helen Sadri; Andrea M Sartori; Martin Schubert; Kai Sprengel; Stephanie A Stalder; Jivko Stoyanov; Cornelia Stress; Aurora Tatu; Cécile Tawadros; Stéphanie van der Lely; Jens Wöllner; Veronika Zubler; Armin Curt; Jürgen Pannek; Martin W G Brinkhof; Thomas M Kessler
Journal:  BMJ Open       Date:  2020-08-13       Impact factor: 2.692

8.  A Urodynamic Comparison of Neural Targets for Transcutaneous Electrical Stimulation to Acutely Suppress Detrusor Contractions Following Spinal Cord Injury.

Authors:  Sean Doherty; Anne Vanhoestenberghe; Lynsey Duffell; Rizwan Hamid; Sarah Knight
Journal:  Front Neurosci       Date:  2019-12-17       Impact factor: 4.677

9.  Engineered Stem Cells Improve Neurogenic Bladder by Overexpressing SDF-1 in a Pelvic Nerve Injury Rat Model.

Authors:  Guan Qun Zhu; Seung Hwan Jeon; Kyu Won Lee; Hyuk Jin Cho; U-Syn Ha; Sung-Hoo Hong; Ji Youl Lee; Eun Bi Kwon; Hyo-Jin Kim; Soon Min Lee; Hey-Yon Kim; Sea Woong Kim; Woong Jin Bae
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

10.  Video-Urodynamic Characteristics and Predictors of Switching from Botulinum Neurotoxin a Injection to Augmentation Enterocystoplasty in Spinal Cord Injury Patients.

Authors:  Chih-Chieh Lin; Hann-Chorng Kuo
Journal:  Toxins (Basel)       Date:  2022-01-10       Impact factor: 4.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.